Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Deutsche Bank AG

Deutsche Bank AG lessened its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 307,769 shares of the company's stock after selling 237,820 shares during the quarter. Deutsche Bank AG owned about 0.49% of Evolus worth $3,398,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Nantahala Capital Management LLC boosted its holdings in shares of Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock valued at $34,557,000 after purchasing an additional 305,300 shares during the last quarter. Caligan Partners LP boosted its holdings in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after purchasing an additional 498,900 shares during the last quarter. Boothbay Fund Management LLC boosted its holdings in shares of Evolus by 30.9% in the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock valued at $14,217,000 after purchasing an additional 304,065 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Evolus by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock valued at $13,412,000 after purchasing an additional 3,969 shares during the last quarter. Finally, Soros Fund Management LLC boosted its holdings in shares of Evolus by 29.4% in the 4th quarter. Soros Fund Management LLC now owns 1,100,000 shares of the company's stock valued at $12,144,000 after purchasing an additional 250,000 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.12 during midday trading on Friday, hitting $9.68. The company's stock had a trading volume of 462,704 shares, compared to its average volume of 693,032. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The firm's fifty day moving average price is $11.04 and its 200-day moving average price is $12.18. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a market cap of $624.13 million, a P/E ratio of -10.64 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EOLS. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. BTIG Research assumed coverage on shares of Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.75.

Insider Activity

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the transaction, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sandra Beaver sold 6,494 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total transaction of $65,069.88. Following the transaction, the chief financial officer now directly owns 167,089 shares of the company's stock, valued at $1,674,231.78. The trade was a 3.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 86,241 shares of company stock valued at $1,048,666. Company insiders own 5.90% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.